On December 1, 2025, the United States and United Kingdom announced a new agreement on pharmaceuticals, pharmaceutical ingredients, and medical technology. Under this arrangement, the U.S. would remove Section 232 tariffs on U.K.-sourced medical goods, pause any Section 301 investigations related to U.K. pharmaceutical pricing during President Trump’s term, and collaborate to expand U.K. patient…

The U.S. Food and Drug Administration announced the rollout of agency-wide agentic AI tools designed to support employees with complex, multi-step tasks. These systems build on the FDA’s earlier deployment of its LLM-based tool, Elsa-currently used voluntarily by a majority of staff-and introduce more advanced features for workflow automation, planning, and reasoning. Participation remains optional,…

CBP is enhancing Section 321 enforcement within ACE to ensure compliance with the $800 de minimis threshold. Starting June 26, the update will be deployed to the CERT environment. This enhancement will prevent the release of shipments claiming de minimis entry when the $800 per person per day limit has already been exceeded, helping to…

The Office of Foreign Assets Control issued a penalty notice for almost $216M on GVA Capital Ltd. They’re a venture capital firm in California. This is for violating the Russia sanctions and failing to comply with a subpoena. Read More